Page 118 - 南京医科大学学报自然科学版
P. 118
第41卷第7期
·1048 · 南 京 医 科 大 学 学 报 2021年7月
影响IFX治疗CD疗效的因素众多,既往研究发 perience[J]. Aliment Pharmacol Ther,2011,33(8):857-
现可能的影响因素包括疾病和临床相关因素(性 869
别、年龄、体重、吸烟、病程、病变部位、疾病行为、疾 [7] LOLY C,BELAICHE J,LOUIS E. Predictors of severe
Crohn’s disease[J]. Scand J Gastroenterol,2008,43(8):
病活动度、合并症)、血液和粪便指标(C 反应蛋白、
948-954
粪钙卫蛋白、血红蛋白、中性粒细胞⁃淋巴细胞比率、
[8] BEAUGERIE L,SEKSIK P,NION⁃LARMURIER I,et al.
白蛋白)、免疫原性(ANCA、抗药抗体等)、既往治疗
Predictors of Crohn’s disease[J]. Gastroenterology,
方案、药物基因组学、微生物和代谢标志物(胆汁
2006,130(3):650-656
[18]
酸、氨基酸和脂质途径的改变) 以及血液和粪便 [9] 杨荣萍,高 翔,何 瑶,等. 克罗恩病预后不良预测因
衍生的参数等,尽管大量研究发现了影响 IFX 疗效 素的研究[J]. 胃肠病学,2012,17(3):151-155
的因素,但目前没有一种决定性的预测指标 [14-17] 。 [10] 胡品津. 炎症性肠病诊断与治疗的共识意见(2012年·
因此,结合诸多影响IFX疗效因素,建立预测IFX疗 广州)[J]. 中华内科杂志,2012,17(10):818-831
效的模型,为个性化治疗提供有效工具,可能成为未 [11] ZENG Z,ZHU Z,YANG Y,et al. Incidence and clinical
来研究的重点 [18] 。本研究评估了与CD特征相关的 characteristics of inflammatory bowel disease in a deve ⁃
4 个高危因素,其他危险因素如吸烟、初次发病即使 loped region of Guangdong Province,China:a prospective
population ⁃ based study[J]. J Gastroenterol Hepatol,
用激素、抗TNF谷浓度、既往手术史等均未纳入研究。
2013,28(7):1148-1153
总之,影响 IFX 治疗 CD 疗效的因素众多,且存
[12] BENMASSAOUD A,AL⁃TAWEEL T,SASSON M S,et al.
在争议,本研究评估 CD 患者合并高危因素的数目
Comparative effectiveness of infliximab versus adalimum⁃
及疾病特征(病变范围和肛周病变)对IFX治疗后的 ab in patients with biologic ⁃ naïve Crohn’s disease[J].
临床应答及黏膜愈合情况的影响,发现合并高危因 Dig Dis Sci,2018,63(5):1302-1310
素多、广泛肠道受累及肛周病变的 CD 患者,IFX 治 [13] OUSSALAH A,DANESE S,PEYRIN⁃BIROULET L. Effi⁃
疗后第2、6、14周的临床应答率及第38周的黏膜愈 cacy of TNF antagonists beyond one year in adult and pe⁃
合率有降低趋势,可为综合评估CD患者疾病状态、 diatric inflammatory bowel diseases:a systematic review
预测IFX疗效提供参考。 [J]. Curr Drug Targets,2010,11(2):156-175
[14] ATREYA R,NEURATH M F,SIEGMUND B. Personaliz⁃
[参考文献]
ing treatment in IBD:hype or reality in 2020? can we pre⁃
[1] LO B,VESTER⁃ANDERSEN M K,VIND I,et al. Chan⁃ dict response to anti⁃TNF?[J]. Front Med(Lausanne),
ges in disease behaviour and location in patients with 2020,7:517
Crohn’s disease after seven years of follow⁃up:a Danish [15] GONCZI L,VEGH Z,GOLOVICS P A,et al. Prediction of
population⁃based inception cohort[J]. J Crohns Colitis, short⁃ and medium⁃term efficacy of biosimilar infliximab
2018,12(3):265-272 therapy. Do trough levels and antidrug antibody levels or
[2] 刘 笑,方 淼,王 方,等. 克罗恩病营养支持治疗进 clinical and biochemical markers play the more important
展[J]. 南京医科大学学报(自然科学版),2020,40 role?[J]. J Crohns Colitis,2017,11(6):697-705
(12):1874-1878,1884 [16] KENNEDY N A,HEAP G A,GREEN H D,et al. Predic⁃
[3] SANDBORN W J. Current directions in IBD therapy:what tors of anti⁃TNF treatment failure in anti⁃TNF⁃naive pa⁃
goals are feasible with biological modifiers?[J]. Gastroen⁃ tients with active luminal Crohn’s disease:a prospective,
terology,2008,135(5):1442-1447 multicentre,cohort study[J]. Lancet Gastroenterol Hepa⁃
[4] CHOWERS Y,ALLEZ M. Efficacy of anti⁃TNF in Crohn’ tol,2019,4(5):341-353
s disease:how does it work?[J]. Curr Drug Targets,2010, [17] LOPETUSO L R,GERARDI V,PAPA V,et al. Can we
11(2):138-142 predict the efficacy of anti⁃TNF⁃α agents?[J]. Int J Mol
[5] HENDLER S,COHEN B L,COLOMBEL J F,et al. High⁃ Sci,2017,18(9):1973
dose infliximab therapy in Crohn’s disease:clinical expe⁃ [18] HLAVATY T,FERRANTE M,HENCKAERTS L,et al.
rience,safety,and efficacy[J]. J Crohns Colitis,2015,9 Predictive model for the outcome of infliximab therapy in
(3):266-275 Crohn’s disease based on apoptotic pharmacogenetic in⁃
[6] DANESE S,COLOMBEL J F,REINISCH W,et al. Re⁃ dex and clinical predictors[J]. Inflamm Bowel Dis,2007,
view article:infliximab for Crohn’s disease treatment ⁃ 13(4):372-379
shifting therapeutic strategies after 10 years of clinical ex⁃
[收稿日期] 2020-11-17